A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

Sponsor
Hoffmann-La Roche
Study ID
NCT02774278
Phase
PHASE2
Status
Completed

Conditions

  • Non-Squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.

Study Details

This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.

Key Dates

First listed
May 17, 2016
Start date
Jul 31, 2005
Status verified
Aug 2016
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009

Study Design

Enrollment
264 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.

Primary Outcome Measure

Number of Differentially Expressed Genes Associated With Clinical Benefit [ Time Frame: Baseline until disease progression, unacceptable toxicity or death, evaluated up to 4 years ]

Related Studies